Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AB Science S.A

ABSCF
Current price
0.90 USD 0 USD (0.00%)
Last closed 1.63 EUR
ISIN FR0010557264
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange PA
Capitalization 105 113 977 EUR
Yield for 12 month -54.74 %
1Y
3Y
5Y
10Y
15Y
ABSCF
21.11.2021 - 28.11.2021

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France. Address: 3, avenue George V, Paris, France, 75008

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

18.50 EUR

P/E ratio

Dividend Yield

Current Year

+967 277 EUR

Last Year

+955 311 EUR

Current Quarter

+558 428 EUR

Last Quarter

+260 267 EUR

Current Year

+585 352 EUR

Last Year

+924 398 EUR

Current Quarter

+267 248 EUR

Last Quarter

+178 498 EUR

Key Figures ABSCF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -8 557 908 EUR
Operating Margin TTM -639.64 %
PE Ratio
Return On Assets TTM -18.16 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 18.50 EUR
Revenue TTM 1 078 962 EUR
Book Value -0.41 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 25.00 %
Dividend Yield
Gross Profit TTM 822 684 EUR
Earnings per share -0.070 EUR
Diluted Eps TTM -0.070 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ABSCF

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ABSCF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ABSCF

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 110.34
Price Sales TTM 97.42
Enterprise Value EBITDA -25.97
Price Book MRQ

Financials ABSCF

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABSCF

For 52 weeks

0.77 EUR 4.45 EUR
50 Day MA 0.95 EUR
Shares Short Prior Month
200 Day MA 1.23 EUR
Short Ratio
Shares Short
Short Percent